Show simple item record

dc.contributor.authorSencan, Orhan
dc.contributor.authorCevik, Duygu
dc.contributor.authorCamci, Celalettin
dc.contributor.authorKilickap, Saadettin
dc.contributor.authorOzdener, Fatih
dc.contributor.authorYalcin, Suayib
dc.contributor.authorUslu, Ruchan
dc.contributor.authorDane, Faysal
dc.contributor.authorYilmaz, Ugur
dc.contributor.authorZengin, Nurullah
dc.contributor.authorBuyukunal, Evin
dc.contributor.authorBuyukberber, Suleyman
dc.date.accessioned2021-03-04T09:46:34Z
dc.date.available2021-03-04T09:46:34Z
dc.identifier.citationYalcin S., Uslu R., Dane F., Yilmaz U., Zengin N., Buyukunal E., Buyukberber S., Camci C., Sencan O., Kilickap S., et al., "Bevacizumab (BEV) plus capecitabine as maintenance therapy after initial treatment with BEV plus XELOX in previously untreated patients (pts) with metastatic colorectal cancer (mCRC): Mature data from STOP and GO, a phase III, randomized, multicenter study", 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 1 - 06 Haziran 2012, cilt.30
dc.identifier.othervv_1032021
dc.identifier.otherav_69d5f151-f3c8-48f7-ac1e-a95e70488d98
dc.identifier.urihttp://hdl.handle.net/20.500.12627/73292
dc.language.isoeng
dc.subjectSağlık Bilimleri
dc.subjectDahili Tıp Bilimleri
dc.subjectİç Hastalıkları
dc.subjectOnkoloji
dc.subjectKlinik Tıp (MED)
dc.subjectTıp
dc.subjectKlinik Tıp
dc.subjectONKOLOJİ
dc.titleBevacizumab (BEV) plus capecitabine as maintenance therapy after initial treatment with BEV plus XELOX in previously untreated patients (pts) with metastatic colorectal cancer (mCRC): Mature data from STOP and GO, a phase III, randomized, multicenter study
dc.typeBildiri
dc.contributor.department, ,
dc.identifier.volume30
dc.contributor.firstauthorID139600


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record